06/05/2024
📝 **Statement on Recent FDA Advisory Panel Decision on M**A-Assisted Therapy for PTSD**
https://www.npr.org/sections/shots-health-news/2024/06/04/nx-s1-4991112/mdma-therapy-ptsd-fda-advisors
I am deeply disappointed by the recent decision of the FDA advisory panel to reject M**A-assisted therapy for PTSD. This setback is disheartening for all of us who believe in the transformative potential of this therapy, as demonstrated by significant positive outcomes in numerous studies, including the groundbreaking *Nature Medicine* article from October 2023.
M**A-assisted therapy has shown incredible promise in reducing and potentially remitting PTSD symptoms, offering hope to many who have not found relief through traditional treatments. The decision of the panel, despite the compelling evidence, underscores the need for continued advocacy and rigorous, transparent research.
I urge the FDA to consider the profound impact this therapy could have on the lives of countless individuals suffering from PTSD. It is crucial that we push forward with the approval process to make M**A-assisted therapy a viable treatment option, ensuring it is conducted safely and effectively.
Together, let’s continue to advocate for the acceptance and availability of innovative therapies that have the potential to change lives for the better.
**A